Viking Therapeutics plans to advance oral obesity drug to late-stage trial
ReutersFeb 11, 2026 10:08 PM
Feb 11 (Reuters) - Viking Therapeutics VKTX.O said on Wednesday that it plans to test its experimental oral obesity drug in a late-stage study later this year.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Best AI Tools for Stock Analysis in 2026 to Boost Your Investment Portfolio
As Artificial Intelligence (AI) continues to enhance everyday decision-making, these tools will allow us to leverage artificial intelligence to analyse stocks and optimise our investment portfolio.TradingKey
14 hours ago
Strategy Defies DAT Sell-Off, Doubles Down Amid Leverage Woes
MicroStrategy acquired over 1,000 additional Bitcoins last week, with Michael Saylor stating the company will purchase Bitcoin every quarter moving forward.TradingKey
16 hours ago
Silver Faces Sixth Consecutive Year of Supply Deficit, How Much Upside Is Left in 2026?
TradingKey - According to the 2026 Silver Market Outlook recently released by the Silver Institute, the current robust performance of the silver market remains supported by solid fundamentals. The report indicates that the global silver market is expected to face a structural supply-demand imbalanceTradingKey
20 hours ago
Retail Trading Hub Robinhood Sinks Again, Slumping Over 7% After Hours, Signaling Lack of Interest in Crypto?
TradingKey - Robinhood (HOOD) reported a 34% decline in fourth-quarter net profit to $605 million, with total revenue of $1.28 billion missing Wall Street expectations.TradingKey
20 hours ago
After $20B Debt Sale, Google’s Rare 100-Year Bond Sparks Scrutiny: Has AI Drained the Tech Giant’s Coffers?
TradingKey - According to a Financial Times report, Google parent Alphabet (GOOG)(GOOGL) is planning to issue bonds denominated in British pounds and Swiss francs, which may include the first 100-year GBP bond of this century.TradingKey
Tue, Feb 10
